SPY
760.15
+0.04%
QQQ
690.26
−0.02%
BTC/USD
71,937.00
−2.69%
DIA
525.39
+0.18%
GLD
355.44
−2.66%
TLT
79.85
−1.33%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Upgrades
What's Going on with Taiwan Semiconductor Stock on Thursday?
AMD Stock Upgraded as AI Chip Rival Nvidia Spirals
This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
AMD Stock Upgraded as AI Chip Rival Nvidia Spirals
This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
This Riot Platforms Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
This Riot Platforms Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
This Centrus Energy Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Read More...
Upgrades Recent News
This Materion Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded Materion, Lyntris, Acadian Asset Management, ZoomInfo and JetBlue, with several price-target increases.
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Wall Street analysts upgraded EW, MSGK, OUST, NVTS; EW, OUST and NVTS also received price-target updates.
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Twilio, Marsh & McLennan, Howmet Aerospace and Aon, raising targets; another analyst moved Aon to Market Perform.
CrowdStrike's AI Opportunity May Be Bigger Than Wall Street Thinks, Analyst Says
Deutsche Bank upgrades CrowdStrike (CRWD) to Buy with a $300 target, citing underestimated AI demand and robust cybersecurity growth.
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded PMT, MHK, CRWD, INO and AON; targets rose for MHK, CRWD and INO, while PMT’s target fell.
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
QUICK SPARK: Intel Stock Drops 28%, Eyes Worst Day Since July 1974
Intel sank 29%, on pace for its worst day since July 1974, as Bank of America's Vivek Arya cut it to Neutral with a $100 target.
This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday
Analysts upgraded Pentair to Neutral with a $65 target and Sun Life Financial to Outperform, raising its target to C$122.
This Broadcom Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday
Analysts upgraded MTSI, KNF, BMI and AVGO; Broadcom’s target rose to $400, while targets were set for MTSI and BMI.
Roper Technologies Analyst Turns Bullish After Q3 Print
JPMorgan upgraded Roper to Neutral rating and raised its target citing organic growth, earnings and software M&A outlook.
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded SAFE, CNOB, LMT and more.
Why Is Allegion Stock Gaining Friday?
Allegion shares climb after Bank of America upgrades the stock and raises its price forecast from $164 to $200.
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Loading...
Loading watchlists...